Journal of the American College of Cardiology
Volume 68, Issue 12, 20 September 2016, Pages 1265-1267
Original InvestigationEditorial CommentPost-Mortem Cardiovascular Implantable Electronic Device Interrogation: Clinical Indications and Potential Benefits∗
Editorial Comment
Under an Elsevier user license
open archive
Key Words
defibrillator
non-sudden death
pacemaker
post-mortem
sudden death
Cited by (0)
Dr. Ackerman is a consultant for Boston Scientific, Gilead Sciences, Invitae, Medtronic, and St. Jude Medical; and from 2004 through 2015, Dr. Ackerman and Mayo Clinic received sales-based royalties from Transgenomic for their FAMILION-LQTS and FAMILION-CPVT genetic tests; however, none of these entities participated in this study. Dr. Giudicessi has reported that he has no relationships relevant to the contents of this paper to disclose.
- ∗
Editorials published in the Journal of the American College of Cardiology reflect the views of the author and do not necessarily represent the views of JACC or the American College of Cardiology.
© 2016 by the American College of Cardiology Foundation Published by Elsevier